NCT03923270 2026-01-08
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
University of Chicago